Head-To-Head Review: Delcath Systems (NASDAQ:DCTH) & Rockwell Medical (NASDAQ:RMTI)

Delcath Systems (NASDAQ:DCTH) and Rockwell Medical (NASDAQ:RMTI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 4.6% of Rockwell Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Delcath Systems and Rockwell Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	6.05%	5.56%	4.98%
Rockwell Medical	-7.33%	-14.03%	-8.90%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Delcath Systems and Rockwell Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	0	1	2	1	3.00
Rockwell Medical	2	0	1	0	1.67

Delcath Systems currently has a consensus target price of $29.33, indicating a potential upside of 43.93%. Rockwell Medical has a consensus target price of $20.00, indicating a potential upside of 186.49%. Given Rockwell Medical’s higher probable upside, analysts plainly believe Rockwell Medical is more favorable than Delcath Systems.

Volatility and Risk

Delcath Systems has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.

Valuation and Earnings

This table compares Delcath Systems and Rockwell Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23 million	8.32	$2.70 million	$0.16	127.37
Rockwell Medical	$69.26 million	0.41	-$5.31 million	($1.34)	-5.21

Delcath Systems has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Summary

Delcath Systems beats Rockwell Medical on 13 of the 15 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

About Rockwell Medical

Rockwell Medical, Inc. is a healthcare company focused on developing, manufacturing and commercializing products used in the treatment of patients with end-stage renal disease (ESRD) who receive hemodialysis. The company supplies products intended to support anemia management and other aspects of dialysis care. Its principal pharmaceutical product is Triferic, an iron replacement therapy designed to deliver iron to hemodialysis patients through the dialysate. Rockwell Medical also markets Triferic AVNU, an intravenous formulation administered during hemodialysis.